Alphamab Oncology Stock
Stocks
9966
KYG0330A1013
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Hong Kong S.E.
04:08:03 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 8.770 HKD | -1.02% |
|
+1.15% | -10.51% |
| Market Cap | 7.27B 8.49B 1.08B 932M 877M 801M 1.5B 102B 1.5B 10.36B 4.02B 52.47B 4.07B 3.98B 169B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 7.27B 8.49B 1.08B 932M 877M 801M 1.5B 102B 1.5B 10.36B 4.02B 52.47B 4.07B 3.98B 169B | EV / Sales 2026 * |
23.2x | EV / Sales 2027 * | 10.8x |
| Free-Float |
49.45% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Hong Kong S.E.
| 9966 | Delayed | |
OTC Markets
| ALMOF | Delayed | |
|
Tradegate
| 3NK | Real-time | |
|
Deutsche Boerse AG
| 3NK | Delayed | |
|
Börse Stuttgart
| 3NK | Delayed | |
|
Boerse Muenchen
| 3NK | Real-time |
| 1 day | -1.02% | ||
| 1 week | +1.15% | ||
| Current month | -2.18% | ||
| 1 month | +11.08% | ||
| 3 months | +26.19% | ||
| 6 months | +12.58% | ||
| Current year | -10.51% |
| 1 week | 8.3 |  | 9.38 |
| 1 month | 7.78 | | 9.38 |
| Current year | 6.23 | | 12.2 |
| 1 year | 6.23 | | 15.75 |
| 3 years | 2 | | 15.75 |
| 5 years | 2 | | 24.9 |
| 10 years | 2 | | 28.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ting Xu
CEO | Chief Executive Officer | 53 | 2018-09-30 |
Fei Wang
DFI | Director of Finance/CFO | - | 2026-03-15 |
Hongwei Wang
CTO | Chief Tech/Sci/R&D Officer | - | 2026-03-10 |
| Director | Title | Age | Since |
|---|---|---|---|
Ting Xu
CHM | Chairman | 53 | 2018-10-30 |
Yang Liu
BRD | Director/Board Member | 54 | 2018-10-30 |
Dong Wu
BRD | Director/Board Member | 56 | 2019-11-23 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.02% | +1.15% | -15.10% | +1.62% | 1.08B | |
| -2.54% | -2.84% | -1.77% | +14.72% | 48.93B | |
| -0.40% | +1.03% | +418.57% | +523.39% | 45.01B | |
| -1.42% | +2.30% | +42.67% | +21.22% | 44.07B | |
| -1.22% | -2.31% | +4.82% | +74.90% | 40.73B | |
| +0.53% | -1.36% | +16.87% | +47.12% | 33.52B | |
| -0.21% | +9.14% | - | - | 17.77B | |
| -0.35% | -1.56% | +21.42% | +123.04% | 16.5B | |
| -1.01% | +0.50% | +13.91% | +31.45% | 14.67B | |
| -1.65% | -1.03% | +75.93% | +41.22% | 13.77B | |
| Average | -0.93% | +0.60% | +64.15% | +97.63% | 27.61B | |
| Weighted average by Cap. | -1.03% | +0.11% | +88.98% | +127.40% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 314M 367M 46.76M 40.23M 37.85M 34.58M 64.69M 4.41B 64.86M 447M 174M 2.26B 176M 172M 7.3B | 673M 786M 100M 86.3M 81.19M 74.17M 139M 9.47B 139M 959M 372M 4.86B 377M 368M 15.65B |
| Net income | - | - |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-04 | HK$8.770 | -1.02% | 434,000 |
| 26-09-03 | HK$8.860 | +3.38% | 1,119,000 |
| 26-09-02 | HK$8.570 | +1.66% | 1,502,000 |
| 26-09-01 | HK$8.430 | -5.97% | 1,446,000 |
| 26-08-31 | HK$8.965 | +3.40% | 3,070,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 9966 Stock
Select your edition
All financial news and data tailored to specific country editions
